Targeting MarA N‐terminal domain dynamics to prevent DNA binding
Protein Science · 2025
DOI: 10.1002/pro.5258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2025. Verfasst von Marina Corbella und 6 weiteren Autor:innen. Beteiligte Einrichtung: Science for Life Laboratory, Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Molecular Dynamics Simulation. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, UK Research and Innovation, Universitat Autònoma de Barcelona.
Abstract (Originalsprache)
Efflux is one of the mechanisms employed by Gram‐negative bacteria to become resistant to routinely used antibiotics. The inhibition of efflux by targeting their regulators is a promising strategy to re‐sensitize bacterial pathogens to antibiotics. AcrAB–TolC is the main resistance‐nodulation‐division efflux pump in Enterobacteriaceae. MarA is an AraC/XylS family global regulator that regulates more than 40 genes related to the antimicrobial resistance phenotype, including acrAB . The aim of this work was to understand the role of the N‐terminal helix of MarA in the mechanism of DNA binding. An N‐terminal deletion of MarA showed that the N‐terminal helix is critical for recognition of the functional marboxes. By engineering two double cysteine variants of MarA that form a disulfide bond between the N‐terminal helix and the hydrophobic core of one of the helices in direct DNA contact, and combining in vitro electrophoretic mobility assays, in vivo measurements of acrAB transcription using a GFP reporter system, and molecular dynamic simulations, it was shown that the immobilization of the N‐terminal helix of MarA prevents binding to DNA. This inhibited conformation seems to be universal for the monomeric members of the AraC/XylS family, as suggested by additional molecular dynamics simulations of the two‐domain protein Rob. These results point to the N‐terminal helix of the AraC/XylS family monomeric regulators as a promising target for the development of inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science for Life Laboratory, Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden.
- Departament de Quı́mica Inorgànica i Orgànica (Secció de Quı́mica Orgànica) & Institut de Quı́mica Teòrica i Computacional (IQTCUB), Universitat de Barcelona, Barcelona, Spain.
- Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, USA.
- College of Medicine and Health, Department of Microbes, Infection and Microbiomes, Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
ORCID-Profile: Roberto Bello-Madruga, Shina C L Kamerlin, Enea Sancho-Vaello
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- UK Research and Innovation
- Universitat Autònoma de Barcelona
- Swedish Research Council
- Knut and Alice Wallenberg Foundation
- Spanish Ministry of Science and Innovation
- Vetenskapsrådet
- Knut och Alice Wallenbergs Stiftelse
Zitieren
APA
Corbella, M., Moreira, C., Bello-Madruga, R., Torrent Burgas, M., Kamerlin, S. C. L., Blair, J. M. A., & Sancho-Vaello, E. (2025). Targeting MarA N‐terminal domain dynamics to prevent DNA binding. Protein Science. https://doi.org/10.1002/pro.5258
Vancouver
Corbella M, Moreira C, Bello-Madruga R, Torrent Burgas M, Kamerlin SCL, Blair JMA, et al. Targeting MarA N‐terminal domain dynamics to prevent DNA binding. Protein Science. 2025. doi:10.1002/pro.5258
BibTeX
@article{Corbella2025,
author = {Corbella, Marina and Moreira, Cátia and Bello-Madruga, Roberto and Torrent Burgas, Marc and Kamerlin, Shina C L and Blair, Jessica M A and Sancho-Vaello, Enea},
title = {Targeting MarA N‐terminal domain dynamics to prevent DNA binding},
journal = {Protein Science},
year = {2025},
doi = {10.1002/pro.5258}
}
EUVIMED